What Does the ELTS Risk Score Mean in Ph+ CML Patients?

The ELTS (EUTOS Long-Term Survival) risk score is a baseline tool doctors use when you are first diagnosed with chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (CML). It is used to estimate the statistical probability of a patient eventually dying specifically from CML, rather than from other causes ^[1].

While the score helps guide the choice of your initial targeted therapy (a tyrosine kinase inhibitor, or TKI), it is only a population-level baseline estimate. The ELTS score is not a crystal ball for your individual outcome or lifespan. How well your leukemia actually responds to treatment over time is a much stronger predictor of your long-term health than your initial score.

How the ELTS Score is Calculated

Your doctor will calculate your ELTS score using a mathematical formula based on four specific pieces of information gathered from your blood work and physical exam at the time of diagnosis ^[1]:

• Age: Your age when diagnosed.
• Spleen size: How enlarged your spleen is, usually measured by feeling how far it extends below your rib cage, or via imaging.
• Peripheral-blood blasts: The percentage of immature leukemia cells (blasts) in your bloodstream.
• Platelet count: The number of blood-clotting cells in your blood.

Based on these four factors, the calculator classifies your disease into one of three risk categories: low, intermediate, or high risk ^[1].

What the Risk Categories Mean

It is natural to feel anxious if you are placed in a higher risk category, but it is essential to understand what these statistics mean. The ELTS score predicts outcomes for large groups of people over time, not your personal odds. Even in the high-risk category, most patients live long lives on modern therapies.

In one real-world study of patients taking TKIs, the 5-year rate of CML-related mortality was 2% for the low-risk group, 5% for the intermediate-risk group, and 11% for the high-risk group ^[2].

The score also predicts how likely a group of patients is to achieve a deep molecular response (DMR) (such as MR4 or MR4.5)—a state where the leukemia fusion gene is barely detectable in the blood. In one study of patients on their first TKI, a deep molecular response was eventually achieved by 65% of low-risk patients, 44% of intermediate-risk patients, and 23.5% of high-risk patients ^[3]. Patients with a higher ELTS score also have a slightly higher risk of early treatment failure ^[4][5].

How Your Score Influences Treatment Decisions

Your ELTS score is one of several factors your doctor will use in shared decision-making to recommend your first TKI.

• Low Risk: For patients with a low ELTS score, imatinib (often available as a generic) is highly effective and frequently the preferred first-line choice ^[6].
• Intermediate or High Risk: For patients with higher risk scores, doctors may consider starting with a “second-generation” TKI, such as dasatinib, nilotinib, or bosutinib ^[7]. These newer medications often produce faster and deeper molecular responses ^[8][9]. However, achieving a faster response does not necessarily equate to better overall survival compared to imatinib.

A second-generation TKI may be favored if you are younger and your ultimate goal is treatment-free remission (TFR) ^[7][8]. TFR is a strictly supervised medical strategy where selected patients who have maintained a deep molecular response for years can attempt to stop their TKI under frequent monitoring. It is not an option for everyone, it requires a plan to immediately restart therapy if the leukemia returns, and you must never stop your medication without your doctor’s explicit direction.

Importantly, your ELTS score never dictates your treatment in isolation because TKIs have different side effects ^[9]. Nilotinib is associated with arterial and metabolic risks; dasatinib is linked to fluid around the lungs (pleural effusion) and pulmonary hypertension; and bosutinib can cause gastrointestinal and liver issues ^[10][9]. If you have a history of heart disease, diabetes, or lung issues, your doctor will carefully choose a drug that minimizes those specific risks, regardless of your ELTS score ^[11].

Why Your Ongoing Response Matters Most

Your ELTS score is a snapshot taken on the day you were diagnosed ^[4]. Once you begin taking a TKI, your actual response to the medication becomes the most important factor in your care.

Doctors monitor your response using a PCR (polymerase chain reaction) test. This test measures the amount of the BCR::ABL1 fusion transcript (the genetic signal of the leukemia) in your blood on a standardized scale called the International Scale (IS) ^[6]. Testing is typically done at 3, 6, and 12 months, and less frequently once your response is stable.

General optimal milestones include ^[6]:

• 3 months: BCR::ABL1 ≤ 10%
• 6 months: BCR::ABL1 ≤ 1%
• 12 months: BCR::ABL1 ≤ 0.1% (Major Molecular Response)

If you meet these milestones, you are responding well, regardless of your initial ELTS score ^[6][4].

If you do not meet a milestone, it does not mean your doctor will immediately switch your medication. Missing a milestone usually prompts a review of how well you have been able to take your medication (adherence), checks for drug interactions (like acid-reducing medicines), a repeat PCR test, or a test for genetic mutations ^[4]. A change in treatment is carefully considered only if a true treatment failure is confirmed.